|
(V897) |
Lysyl oxidase-like-2 inhibition decreases cardiac fibrosis and improves diastolic dysfunction in experimental and clinical heart failure with preserved ejection fractionEndFragment |
| |
|
K. Savvatis, M. Kasner, S. Van Linthout, H.-P. Schultheiss, C. Tschöpe (Berlin) |
|
|
Diskussion |
|
(V898) |
Changes in B-type natriuretic Peptide after implantation of Left Ventricular Assist Device: Results in the first year after implantation of a continuous flow devices. |
| |
|
P. Aurich, S. Alotaibi, P. Krings, N. Reinsch, P. Kahlert, M. Goetjes, R. Erbel, T. Neumann (Essen) |
|
|
Diskussion |
|
(V899) |
Should procalcitonin be measured routinely in acute decompensated heart failure? Results from the MOLITOR Trial |
| |
|
G. Loncar, T. D. Trippel, E. Tahirovic, J. Veskovic, A. Marx, V. Tscholl, D. Obradovic, M. Lainscak, A. Arandjelovic, N. Sekularac, S. von Haehling, B. Pieske, H.-D. Düngen , KNHI (Belgrad, CS; Berlin, Nürnberg; Golnik, SI) |
|
|
Diskussion |
|
(V900) |
Growth differentiation factor-15 (GDF-15): A prognostic marker for heart failure and death from cardiovascular disease in the BiomarCaRE Cohort Glostrup |
| |
|
N. Fluschnik, F. Ojeda-Echevarria, T. Zeller, T. Jørgensen, K. Kuulasmaa, S. Blankenberg, D. Westermann (Hamburg; Glostrup, DK; Helsinki, FI) |
|
|
Diskussion |
|
(V901) |
Circulating annexin A5 predicts mortality in patients with heart failure |
| |
|
M. Burgmaier, L. Schurgers, T. Ueland, K. Schutters, S. Aakhus, L. Hofstra, L. Gullestad, P. Aukrust, M. Hellmich, J. Narula, N. Marx, C. Reutelingsperger (Aachen, Oslo, Köln; Maastricht, NL; Oslo, NO; New York, US) |
|
|
Diskussion |
|
(V902) |
Impairment of the angiogenic potential of the bone marrow microenvironment predicts cardiovascular death in patients with chronic heart failure |
| |
|
K. Sopova, L. Palapies, D. Leistner, K. Stellos, S. Fichtlscherer, F. Seeger, S. Dimmeler, B. Aßmus, A. M. Zeiher, T. Keller (Frankfurt am Main, Mannheim) |
|
|
Diskussion |